INBS

+ Watchlist + Portfolio

Intelligent Bio Solutions Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.66
52-Week Range: $1.52 – $24.90
Market Cap: $5.51M
P/E (TTM): —
EPS (TTM): -8.44
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.88
PEG Ratio: —
Return on Equity: -307.69%
Return on Assets: -76.20%
Gross Margin: 48.63%
Operating Margin: -345.98%
Profit Margin: -294.91%
Current Ratio: 1.44
Debt/Equity: 0.34
Total Debt: $1.82M
Free Cash Flow: $-6.72M
Revenue Growth: 35.80%
Earnings Growth: —
Enterprise Value: $2.48M

INBS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$0.00	$1.26M	$3.11M	$3.05M	$4.22M
Cost of Revenue	$0.00	$930.20K	$1.69M	$1.81M	$2.17M
Gross Profit	$0.00	$326.67K	$1.43M	$1.25M	$2.05M
Research & Development	$3.85M	$507.42K	$1.67M	$2.40M	$3.37M
Selling, General & Admin	$4.92M	$8.03M	$9.26M	$8.92M	$10.50M
Operating Expenses	$8.34M	$8.76M	$11.71M	$11.71M	$14.36M
Operating Income	-$8.34M	-$8.44M	-$10.28M	-$10.46M	-$12.31M
EBITDA	-$8.33M	-$9.47M	-$8.81M	-$9.37M	-$11.29M
Pretax Income	-$8.33M	-$10.66M	-$10.19M	-$10.60M	-$12.47M
Net Income	-$8.31M	-$10.63M	-$10.16M	-$10.57M	-$12.43M
Diluted EPS	-1368.00	-1270.00	-63.80	-20.04	—
Diluted Shares	6110	8371	159274	527364	—

INBS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$8.24M	$1.54M	$6.30M	$1.02M	$3.99M
Receivables	$2.47M	$833.16K	$978.35K	$1.67M	$1.67M
Inventory	$0.00	$979.91K	$777.54K	$635.22K	$418.58K
Current Assets	$10.87M	$3.86M	$8.53M	$4.14M	$7.10M
Total Assets	$12.35M	$10.35M	$13.78M	$8.25M	$11.94M
Current Liabilities	$4.66M	$5.88M	$5.45M	$5.35M	$4.93M
Long-Term Debt	—	$402.86K	—	—	—
Total Debt	$0.00	$1.34M	$871.44K	$281.81K	$1.82M
Total Liabilities	$5.81M	$6.67M	$5.60M	$5.44M	$6.65M
Retained Earnings	-$31.18M	-$41.81M	-$51.96M	-$62.53M	-$74.96M
Shareholders' Equity	$6.62M	$3.80M	$8.33M	$3.00M	$5.51M
Working Capital	$6.20M	-$2.02M	$3.08M	-$1.21M	$2.17M

INBS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$3.36M	-$7.38M	-$9.57M	-$9.68M	-$11.93M
Capital Expenditure	-$380.22K	-$505.12K	-$221.43K	-$231.84K	-$125.73K
Free Cash Flow	-$3.74M	-$7.88M	-$9.79M	-$9.91M	-$12.05M
Depreciation & Amortisation	$0.00	$966.73K	$1.21M	$1.21M	$1.16M
Stock-Based Compensation	$0.00	$260.00K	$230.50K	$238.04K	$195.21K
Investing Cash Flow	-$880.22K	-$694.14K	-$221.43K	-$231.84K	-$85.57K
Financing Cash Flow	$0.00	$1.44M	$14.56M	$4.60M	$14.98M
Net Change in Cash	-$4.24M	-$6.64M	$4.77M	-$5.31M	$2.97M

INBS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$728.87K	$843.88K	$1.11M	$896.77K	$1.06M	$1.15M
Cost of Revenue	$387.50K	$508.31K	$593.51K	$437.04K	$525.42K	$609.22K
Gross Profit	$341.37K	$335.58K	$518.29K	$459.74K	$535.38K	$536.58K
Research & Development	$358.35K	$582.47K	$486.17K	$522.11K	$893.98K	$1.47M
Selling, General & Admin	$2.41M	$2.72M	$2.66M	$2.34M	$2.46M	$2.99M
Operating Expenses	$2.90M	$3.22M	$3.26M	$3.07M	$3.48M	$4.50M
Operating Income	-$2.56M	-$2.88M	-$2.74M	-$2.61M	-$2.94M	-$3.96M
EBITDA	-$2.24M	-$2.79M	-$2.69M	-$2.35M	-$2.58M	-$3.63M
Pretax Income	-$2.55M	-$3.10M	-$2.99M	-$2.69M	-$2.87M	-$3.92M
Net Income	-$2.54M	-$3.09M	-$2.98M	-$2.68M	-$2.86M	-$3.91M
Diluted EPS	-4.41	—	-3.50	-2.82	-1.80	—
Diluted Shares	577191	—	854693	950829	1.59M	—

INBS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$2.81M	$1.02M	$1.66M	$740.37K	$6.86M	$3.99M
Receivables	$1.03M	$1.67M	$1.64M	$10.36M	$1.45M	$1.67M
Inventory	$683.49K	$635.22K	$628.18K	$590.25K	$597.47K	$418.58K
Current Assets	$5.11M	$4.14M	$4.48M	$12.17M	$9.75M	$7.10M
Total Assets	$9.58M	$8.25M	$10.04M	$17.65M	$14.86M	$11.94M
Current Liabilities	$4.56M	$5.35M	$5.06M	$5.13M	$4.61M	$4.93M
Total Debt	$511.18K	$281.81K	$1.95M	$1.92M	$1.85M	$1.82M
Total Liabilities	$4.64M	$5.44M	$6.61M	$6.76M	$6.11M	$6.65M
Retained Earnings	-$59.44M	-$62.53M	-$65.52M	-$68.19M	-$71.06M	-$74.96M
Shareholders' Equity	$5.11M	$3.00M	$3.62M	$11.09M	$8.96M	$5.51M
Working Capital	$542.95K	-$1.21M	-$577.71K	$7.05M	$5.14M	$2.17M

INBS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.76M	-$2.21M	-$2.85M	-$1.57M	-$4.33M	-$3.18M
Capital Expenditure	-$14.38K	-$208.52K	-$70.40K	-$68.23K	—	—
Free Cash Flow	-$2.77M	-$2.42M	-$2.92M	-$1.64M	-$4.32M	-$3.18M
Depreciation & Amortisation	$296.83K	$306.17K	$303.38K	$281.90K	$290.39K	$288.18K
Stock-Based Compensation	$12.00K	$12.00K	$12.00K	$61.58K	$24.20K	$97.43K
Investing Cash Flow	-$14.38K	-$208.52K	-$70.40K	-$28.07K	$12.90K	$0.00
Financing Cash Flow	$3.32M	$602.00K	$3.56M	$674.65K	$10.44M	$311.99K
Net Change in Cash	$551.84K	-$1.82M	$640.94K	-$920.94K	$6.12M	-$2.87M

Market Snapshot

About

Intelligent Bio Solutions Inc. is a medical technology company developing rapid diagnostic testing devices and biosensor platforms. The company's flagship product is a non-invasive saliva-based rapid screening test system for detecting recent drug use, designed for workplace testing, criminal justice, and rehabilitation monitoring applications. INBS combines biosensor technology, microfluidics, and artificial intelligence to create portable diagnostic solutions that deliver lab-quality results at the point of care. The company aims to expand its platform to address multiple diagnostic markets beyond drug screening.